A new trading day began on Monday, with Denali Therapeutics Inc (NASDAQ: DNLI) stock price up 4.49% from the previous day of trading, before settling in for the closing price of $12.70. DNLI’s price has ranged from $10.57 to $33.33 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 260.06% over the past five years. Meanwhile, its annual earnings per share averaged -13.20%. With a float of $125.71 million, this company’s outstanding shares have now reached $142.63 million.
Let’s look at the performance matrix of the company that is accounted for 422 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Denali Therapeutics Inc (DNLI) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Denali Therapeutics Inc is 13.43%, while institutional ownership is 88.03%. The most recent insider transaction that took place on Jan 06 ’25, was worth 247,796. In this transaction Chief Medical Officer of this company sold 12,255 shares at a rate of $20.22, taking the stock ownership to the 178,580 shares. Before that another transaction happened on Jan 07 ’25, when Company’s Chief Medical Officer sold 2,907 for $20.81, making the entire transaction worth $60,495. This insider now owns 175,673 shares in total.
Denali Therapeutics Inc (DNLI) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.71 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -13.20% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 9.16% during the next five years compared to -4.46% drop over the previous five years of trading.
Denali Therapeutics Inc (NASDAQ: DNLI) Trading Performance Indicators
Here are Denali Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 8.46.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.58, a number that is poised to hit -0.70 in the next quarter and is forecasted to reach -2.62 in one year’s time.
Technical Analysis of Denali Therapeutics Inc (DNLI)
Denali Therapeutics Inc (NASDAQ: DNLI) saw its 5-day average volume 1.94 million, a positive change from its year-to-date volume of 1.26 million. As of the previous 9 days, the stock’s Stochastic %D was 52.90%. Additionally, its Average True Range was 1.22.
During the past 100 days, Denali Therapeutics Inc’s (DNLI) raw stochastic average was set at 17.30%, which indicates a significant decrease from 63.23% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 104.35% in the past 14 days, which was higher than the 72.23% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $16.78, while its 200-day Moving Average is $22.73. Nevertheless, the first resistance level for the watch stands at $13.63 in the near term. At $14.00, the stock is likely to face the second major resistance level. The third major resistance level sits at $14.66. If the price goes on to break the first support level at $12.60, it is likely to go to the next support level at $11.94. Assuming the price breaks the second support level, the third support level stands at $11.57.
Denali Therapeutics Inc (NASDAQ: DNLI) Key Stats
With a market capitalization of 1.93 billion, the company has a total of 145,215K Shares Outstanding. Currently, annual sales are 0 K while annual income is -422,770 K. The company’s previous quarter sales were 0 K while its latest quarter income was -114,750 K.
